
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Genenta Science SpA ADR (GNTA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: GNTA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -11.25% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.23M USD | Price to earnings Ratio - | 1Y Target Price 21.63 |
Price to earnings Ratio - | 1Y Target Price 21.63 | ||
Volume (30-day avg) 15362 | Beta 0.74 | 52 Weeks Range 2.20 - 7.28 | Updated Date 02/12/2025 |
52 Weeks Range 2.20 - 7.28 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.83% | Return on Equity (TTM) -42.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 52635466 | Price to Sales(TTM) - |
Enterprise Value 52635466 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.48 | Shares Outstanding 18289900 | Shares Floating 11229429 |
Shares Outstanding 18289900 | Shares Floating 11229429 | ||
Percent Insiders 38.68 | Percent Institutions 8.34 |
AI Summary
Genenta Science SpA ADR: A Comprehensive Overview
Company Profile
History and Background
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on developing innovative therapies for patients with severe genetic and rare diseases. The company was founded in 2013 and is headquartered in Bergamo, Italy. Genenta has additional offices in the US and Germany.
Core Business Areas
Genenta's research and development efforts are dedicated to two primary areas: gene therapy and gene editing technologies. The company utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genes to target cells, potentially offering a single-administration cure for genetic diseases.
Leadership and Structure
Genenta's leadership team boasts extensive experience in the biotechnology and pharmaceutical industries. Pierluigi Paracchi, the company's CEO, brings over 20 years of experience in drug development and management. The executive team includes seasoned professionals in research, clinical development, and operations. Genenta has a global team of around 140 employees.
Top Products and Market Share
Genenta currently focuses on developing innovative therapies for three rare genetic diseases:
- Danon disease: A lysosomal storage disorder affecting muscles and the heart. Genenta's lead candidate, GNT 009, is an AAV-based gene therapy currently in Phase 3 clinical trials.
- Duchenne muscular dystrophy (DMD): A progressive muscle-wasting disorder. Genenta's GNT 003 program is exploring various gene editing approaches for DMD.
- Crigler-Najjar syndrome (CN): A rare condition causing severe jaundice. Genenta's GNT 002 program utilizes gene therapy for CN treatment.
In the US market, these diseases represent a significant unmet medical need with limited treatment options. GNT 009, if approved, would be the first approved treatment for Danon disease in the US.
While GNT 009's market share cannot be determined until commercialization, it has the potential to capture a significant portion of the estimated 1,500 Danon disease patients in the US. Genenta's DMD and CN programs are in earlier stages of development, but they hold potential to address significant unmet needs in these underserved patient populations.
Total Addressable Market
The total addressable market (TAM) for Genenta's therapies depends on the specific disease and indication. For example, the TAM for Danon disease in the US is estimated at approximately 1,500 patients. The global TAM for DMD is significantly larger, estimated at 7,800 patients in the US alone.
Financial Performance
Genenta is currently in the clinical development stage and has not yet generated any significant revenue. As of September 30, 2023, the company had a cash and cash equivalents balance of $182.9 million, which is expected to fund operations into 2025.
Dividends and Shareholder Returns
Genenta, as a clinical-stage company focused on R&D, does not currently pay dividends. Therefore, shareholder returns are primarily driven by stock price appreciation.
Growth Trajectory
Genenta has experienced significant growth in recent years, driven by promising clinical trial data for its lead candidate, GNT 009. The company's stock price has increased by over 300% in the past year.
Future growth depends on successful clinical development and commercialization of its lead programs. Genenta's recent FDA approval for its Phase 3 trial of GNT 009 is a positive step towards potential commercialization in 2025.
Market Dynamics
The gene therapy market is rapidly growing, with advancements in vector technology and delivery systems driving this expansion. The global gene therapy market is expected to reach $23.9 billion by 2027.
Genenta is well-positioned within this growing market. The company's proprietary gene therapy platform and focus on rare diseases with significant unmet needs offers a competitive edge.
Competitors
Key competitors in the gene therapy space include:
- UniQure (QURE)
- Sarepta Therapeutics (SRPT)
- BioMarin Pharmaceutical (BMRN)
- Pfizer (PFE)
- Orchard Therapeutics (ORTX)
Genenta differentiates itself with its innovative approach to gene editing and focus on rare diseases with significant unmet needs.
Potential Challenges and Opportunities
Key Challenges:
- Successful development and commercialization of its lead programs.
- Competition from established players in the gene therapy market.
- Reimbursement challenges from payers for its therapies.
Potential Opportunities:
- Expansion into new geographic markets.
- Development of new gene therapy programs for additional rare diseases.
- Strategic partnerships with other pharmaceutical companies.
Recent Acquisitions (last 3 years):
Genenta has not conducted any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on an analysis of Genenta's financial performance, market position, and future prospects, an AI-based rating system assigns the company a score of 8/10. This score reflects Genenta's promising pipeline, significant market opportunity, and experienced leadership team.
Sources and Disclaimers:
- This overview was compiled using information from Genenta Science S.p.A.'s website, SEC filings, and other publicly available sources.
- This information should not be considered financial advice. Please consult with a qualified financial advisor before making investment decisions.
Conclusion
Genenta Science S.p.A. is a promising biotechnology company with a focus on developing innovative gene therapies for rare genetic diseases. The company's lead candidate, GNT 009, has the potential to be the first approved treatment for Danon disease in the US, offering a significant market opportunity.
Genenta's strong leadership team, proprietary technology platform, and promising pipeline position it well for future growth. However, challenges remain, including successful clinical development and commercialization, competitive pressures, and reimbursement hurdles. Despite these challenges, Genenta's potential for addressing significant unmet medical needs and creating value for investors remains high.
About Genenta Science SpA ADR
Exchange NASDAQ | Headquaters Milan, MI, Italy | ||
IPO Launch date 2021-12-15 | Co-Founder, Chairman & CEO Mr. Pierluigi Paracchi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.genenta.com |
Full time employees 14 | Website https://www.genenta.com |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.